These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 8315262)

  • 21. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid.
    Kuiper EM; Hansen BE; de Vries RA; den Ouden-Muller JW; van Ditzhuijsen TJ; Haagsma EB; Houben MH; Witteman BJ; van Erpecum KJ; van Buuren HR;
    Gastroenterology; 2009 Apr; 136(4):1281-7. PubMed ID: 19208346
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis.
    Kowdley KV; Bowlus CL; Levy C; Akarca US; Alvares-da-Silva MR; Andreone P; Arrese M; Corpechot C; Francque SM; Heneghan MA; Invernizzi P; Jones D; Kruger FC; Lawitz E; Mayo MJ; Shiffman ML; Swain MG; Valera JM; Vargas V; Vierling JM; Villamil A; Addy C; Dietrich J; Germain JM; Mazain S; Rafailovic D; Taddé B; Miller B; Shu J; Zein CO; Schattenberg JM; ;
    N Engl J Med; 2024 Feb; 390(9):795-805. PubMed ID: 37962077
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid.
    Hirschfield GM; Mason A; Luketic V; Lindor K; Gordon SC; Mayo M; Kowdley KV; Vincent C; Bodhenheimer HC; Parés A; Trauner M; Marschall HU; Adorini L; Sciacca C; Beecher-Jones T; Castelloe E; Böhm O; Shapiro D
    Gastroenterology; 2015 Apr; 148(4):751-61.e8. PubMed ID: 25500425
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis.
    Lindor KD; Dickson ER; Baldus WP; Jorgensen RA; Ludwig J; Murtaugh PA; Harrison JM; Wiesner RH; Anderson ML; Lange SM
    Gastroenterology; 1994 May; 106(5):1284-90. PubMed ID: 8174890
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis.
    Hirschfield GM; Bowlus CL; Mayo MJ; Kremer AE; Vierling JM; Kowdley KV; Levy C; Villamil A; Ladrón de Guevara Cetina AL; Janczewska E; Zigmond E; Jeong SH; Yilmaz Y; Kallis Y; Corpechot C; Buggisch P; Invernizzi P; Londoño Hurtado MC; Bergheanu S; Yang K; Choi YJ; Crittenden DB; McWherter CA;
    N Engl J Med; 2024 Feb; 390(9):783-794. PubMed ID: 38381664
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic factors and long-term effects of ursodeoxycholic acid on liver biochemical parameters in patients with primary biliary cirrhosis. Dutch Multi-Centre PBC Study Group.
    van Hoogstraten HJ; Hansen BE; van Buuren HR; ten Kate FJ; van Berge-Henegouwen GP; Schalm SW
    J Hepatol; 1999 Aug; 31(2):256-62. PubMed ID: 10453938
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ten-year combination treatment with colchicine and ursodeoxycholic acid for primary biliary cirrhosis: a double-blind, placebo-controlled trial on symptomatic patients.
    Battezzati PM; Zuin M; Crosignani A; Allocca M; Invernizzi P; Selmi C; Villa E; Podda M
    Aliment Pharmacol Ther; 2001 Sep; 15(9):1427-34. PubMed ID: 11552915
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis?
    Poupon R; Chrétien Y; Poupon RE; Ballet F; Calmus Y; Darnis F
    Lancet; 1987 Apr; 1(8537):834-6. PubMed ID: 2882236
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BAT117213: Ileal bile acid transporter (IBAT) inhibition as a treatment for pruritus in primary biliary cirrhosis: study protocol for a randomised controlled trial.
    Hegade VS; Kendrick SF; Dobbins RL; Miller SR; Richards D; Storey J; Dukes G; Gilchrist K; Vallow S; Alexander GJ; Corrigan M; Hirschfield GM; Jones DE
    BMC Gastroenterol; 2016 Jul; 16(1):71. PubMed ID: 27431238
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis.
    Corpechot C; Chazouillères O; Rousseau A; Le Gruyer A; Habersetzer F; Mathurin P; Goria O; Potier P; Minello A; Silvain C; Abergel A; Debette-Gratien M; Larrey D; Roux O; Bronowicki JP; Boursier J; de Ledinghen V; Heurgue-Berlot A; Nguyen-Khac E; Zoulim F; Ollivier-Hourmand I; Zarski JP; Nkontchou G; Lemoinne S; Humbert L; Rainteau D; Lefèvre G; de Chaisemartin L; Chollet-Martin S; Gaouar F; Admane FH; Simon T; Poupon R
    N Engl J Med; 2018 Jun; 378(23):2171-2181. PubMed ID: 29874528
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response.
    Reig A; Sesé P; Parés A
    Am J Gastroenterol; 2018 Jan; 113(1):49-55. PubMed ID: 29016567
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relationship between biliary and serum bile acids and response to ursodeoxycholic acid in patients with primary biliary cirrhosis.
    Lindor KD; Lacerda MA; Jorgensen RA; DeSotel CK; Batta AK; Salen G; Dickson ER; Rossi SS; Hofmann AF
    Am J Gastroenterol; 1998 Sep; 93(9):1498-504. PubMed ID: 9732932
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis.
    Corpechot C; Abenavoli L; Rabahi N; Chrétien Y; Andréani T; Johanet C; Chazouillères O; Poupon R
    Hepatology; 2008 Sep; 48(3):871-7. PubMed ID: 18752324
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study.
    Hegade VS; Kendrick SF; Dobbins RL; Miller SR; Thompson D; Richards D; Storey J; Dukes GE; Corrigan M; Oude Elferink RP; Beuers U; Hirschfield GM; Jones DE
    Lancet; 2017 Mar; 389(10074):1114-1123. PubMed ID: 28187915
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined treatment with ursodeoxycholic acid and prednisone in primary biliary cirrhosis.
    Wolfhagen FH; van Buuren HR; Schalm SW
    Neth J Med; 1994 Mar; 44(3):84-90. PubMed ID: 8202208
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis.
    Combes B; Emerson SS; Flye NL; Munoz SJ; Luketic VA; Mayo MJ; McCashland TM; Zetterman RK; Peters MG; Di Bisceglie AM; Benner KG; Kowdley KV; Carithers RL; Rosoff L; Garcia-Tsao G; Boyer JL; Boyer TD; Martinez EJ; Bass NM; Lake JR; Barnes DS; Bonacini M; Lindsay KL; Mills AS; Markin RS; Rubin R; West AB; Wheeler DE; Contos MJ; Hofmann AF
    Hepatology; 2005 Nov; 42(5):1184-93. PubMed ID: 16250039
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ursodeoxycholic acid treatment in primary biliary cirrhosis with the emphasis on late stage disease.
    Kneppelhout JC; Mulder CJ; van Berge Henegouwen GP; de Vries RA; Brandt KH
    Neth J Med; 1992 Aug; 41(1-2):11-6. PubMed ID: 1407234
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical significance of serum bilirubin levels under ursodeoxycholic acid therapy in patients with primary biliary cirrhosis.
    Bonnand AM; Heathcote EJ; Lindor KD; Poupon RE
    Hepatology; 1999 Jan; 29(1):39-43. PubMed ID: 9862847
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid.
    Stojakovic T; Putz-Bankuti C; Fauler G; Scharnagl H; Wagner M; Stadlbauer V; Gurakuqi G; Stauber RE; März W; Trauner M
    Hepatology; 2007 Sep; 46(3):776-84. PubMed ID: 17668874
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of ursodeoxycholic acid on hepatic inflammation and histological stage in patients with primary biliary cirrhosis.
    Batts KP; Jorgensen RA; Dickson ER; Lindor KD
    Am J Gastroenterol; 1996 Nov; 91(11):2314-7. PubMed ID: 8931409
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.